Table of Contents
Metal-Based Drugs
Volume 4, Issue 2, Pages 75-80
http://dx.doi.org/10.1155/MBD.1997.75

X-Ray Structure and In Vitro Anti-Tumoural Activity of the Dimeric Bis[(2-Phenyl-1,2-Dicarba-Closo-Dodecaborane-1-Carboxylato)-Di-n-Butyltin] Oxide

1Department of Chemistry, The University of Adelaide, 5005, South Australia, Australia
2Department of General and Organic Chemistry, Faculty of Applied Sciences, Free University of Brussels (V.U.B.), Pleinlaan 2, Brussels B-1050, Belgium
3High Resolution NMR Centre, Free University of Brussels (V.U.B.), Pleinlaan 2, Brussels B-1050, Belgium
4A. N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, Vavilova Str. 28, V-334, Moscow 117813, Russia

Received 12 February 1997; Accepted 7 March 1997

Copyright © 1997 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

X-ray diffraction studies reveal the structure of {[(2-C6H5-1,2-C2B10H10-1-COO)Bu2Sn]2O}2, 1, to conform to the common motif found for {[(RCOO)R2Sn]2O}2 compounds. The dimer features a central Bu4Sn2O2 unit (two-fold symmetry) with the two Bu2Sn groups being linked via bridging oxygen atoms, each of which also carries an exocyclic Bu2Sn moiety. The two pairs of exo- and endo-cyclic tin atoms are each linked via an almost symmetrically bridging carboxylate ligand and the two remaining ligands coordinate an exocyclic tin atom only, in the monodentate mode. The in vitro anti-tumour activity of 1, determined against a variety of cell lines, is compared with those of the corresponding 2-methylcarboranylacetate, derivative 2, and with clinically used compounds.